Mar 4, 2021CFLAA Striving for Better Sleep Quality
Alaxo Airway Stents (Alaxo), providers of FDA-cleared and Health Canada-registered, internationally patented, innovative stent-based therapies to support healthy, natural, nasal breathing solutions to improve sleep, treat snoring and sleep apnea, and enhance athletic performance, announces a partnership with the Canadian Football League Alumni Association (CFLAA), providing innovative stent-based therapies to alumni, their families and friends. Alaxo’s stents support healthy natural nasal breathing and are clinically proven to reduce snoring, enhance sleep and treat sleep apnea – all of which can improve day-to-day health and well-being, as well as athletic performance.
“On behalf of our members and the community we serve, the CFLAA is excited about this new partnership with Canadian-based Alaxo, which offers an important pathway to better, safer sleep,” says Leo Ezerins, Executive Director and Founder, CFLAA. “The CFLAA is committed to providing health and wellness support to its constituents, and by aligning with like-minded partners, such as the Alaxo team, we are realizing our goals.”
Alaxo Airway Stents support natural, nasal breathing to improve sleep, relieve snoring and sleep apnea, and enhance athletic performance. Stents also provide support for health issues that impact quality of life, such as allergies, rhinitis, chronic rhinitis, sinusitis, and allergic rhinitis, as well as many autoimmune diseases. They can be worn for up to 18 hours a day on their own or in conjunction with CPAP machines and oral appliances.
Jack Huber, President, Alaxo, states, “We’re thrilled to partner with CFLAA and launch opportunities for improved health, well-being, and overall quality of life for alumni members. Football in Canada has a long history and is deep in tradition dating back to the 1860s and Alaxo is proud to be a part of it.”
All sales generated through this CFLAA membership opportunity include a donation from Alaxo to CFLAA charities of choice.
To read the full press release, click here.